Literature DB >> 1270931

Halofenate and clofibrate: mechanism of hypotriglyceridemic action in the rat.

R J Cenedella, W G Crouthamel.   

Abstract

Rats fed a fat-free diet containing no drug, 0.02% or 0.10% halofenate, or 0.25% clofibrate for 14 days were injected intravenously with equivalent amounts of either [2-3H]glycerol or [1(3)-3H]glycerol. Blood samples were collected at times up to 150 min after injection and serum triglycerides were isolated and assayed for radioactivity. Kinetic analysis of the serum appearance and clearance curves of 3H-labeled triglyceride permits estimation of serum total 3H-labeled triglyceride formation and triglyceride fractional turnover rates. The total amounts of 3H-labeled triglyceride formed from [2-3H] or from [1(3)-3H] glycerol in control-fed animals were very similar. Over 95% of the serum 3H-labeled triglyceride formed from either substrate circulated in a rapidly turning-over triglyceride pool (t1/2 = 8 min). Treatment with 0.10% halofenate or 0.25% clofibrate decreased labeling of serum triglycerides by 75-80% without increasing serum 3H-labeled triglyceride fractional turnover rates. Furthermore, both drugs decreased incorporation in vivo of 14C from [U-14C]glycerol into hepatic but not intestinal triglycerides without significantly decreasing incorporation of 14C into total phospholipids of either tissue. From these observations we suggest that, in the intact normal rat, sustained reduction of serum triglyceride levels produced by treatment with halofenate or clofibrate is due to inhibition of hepatic triglyceride formation.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1270931

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  5 in total

1.  Hypolipidemic drugs are inhibitors of phosphatidylcholine synthesis.

Authors:  S Parthasarathy; D Kritchevsky; W J Baumann
Journal:  Proc Natl Acad Sci U S A       Date:  1982-11       Impact factor: 11.205

2.  Studies on the mechanism of action of halofenate.

Authors:  L R Mandel
Journal:  Lipids       Date:  1977-01       Impact factor: 1.880

3.  The contribution of serum triacylglycerol to hepatic triacylglycerol turnover in the starved rat.

Authors:  E W Lipkin; C Cooper; R A Shipley
Journal:  Biochem J       Date:  1978-05-15       Impact factor: 3.857

4.  Hypolipidemic effects of clofibrate and selected chroman analogs in fasted rats: I. Chow-fed animals.

Authors:  M O'Brien; S T Patel; A Mukhopadhyay; H A Newman; D R Feller; S S Kokrady; D T Witiak; R R Lanese; J C Rice
Journal:  Lipids       Date:  1981-12       Impact factor: 1.880

5.  MBX-102/JNJ39659100, a novel non-TZD selective partial PPAR-γ agonist lowers triglyceride independently of PPAR-α activation.

Authors:  Apurva Chandalia; Holly J Clarke; L Edward Clemens; Bindu Pandey; Vic Vicena; Paul Lee; Brian E Lavan; Francine M Gregoire
Journal:  PPAR Res       Date:  2009-04-23       Impact factor: 4.964

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.